During his time at Novavax, Rahul Singhvi had a significant influence on the company’s stock performance. At one point, he held stock options with a potential value of over $2 million if the company’s stock price rose. His options included...

During his time at Novavax, Rahul Singhvi had a significant influence on the company’s stock performance. At one point, he held stock options with a potential value of over $2 million if the company’s stock price rose. His options included grants that vested based on performance, aligning his interests with that of shareholders. Initially, he enjoyed a lucrative compensation package but faced declines in stock value as the company struggled, particularly in 2008, causing him to forfeit bonuses. His stock options were a key part of his overall wealth, especially during the hype surrounding vaccine developments in 2006. However, by 2011, as he stepped down under difficult circumstances, the value of his holdings diminished, reflecting the volatility of biotech stocks and company performance.